The 66th ASH Annual Meeting and Exposition is set to take place from December 7-10, 2024, in San Diego, California, as well as online. This event stands as the premier hematology gathering of the year, attracting over 30,000 health professionals, clinicians, researchers, educators, and other industry experts. Attendees can expect a multitude of sessions, thousands of abstracts, and numerous opportunities to engage with the latest advancements in hematology.

To secure your attendance at this esteemed event, we highly recommend registering promptly by clicking here. By doing so, you will have the chance to secure accommodations, access travel information, plan your itinerary, and guarantee your participation in educational and networking activities before they reach full capacity.

The ASH Annual Meeting will feature essential sessions dedicated to bleeding and clotting disorders, focusing on topics such as venous thromboembolism (VTE), immune thrombocytopenia (ITP), Hemophilia A, and more. We are excited to explore these sessions, thoughtfully organized in chronological order for your convenience.

The Expanding Landscape of Treatment for ITP

  • Date/Time: Saturday, December 7, 2024, 9:30 am – 10:45 am
  • Location: San Diego Convention Center, Room 28 A-D
  • Description: The management of Immune Thrombocytopenia (ITP) has undergone a significant transformation in recent years, with a surge in available therapies and a more patient-centered approach. This evolution has resulted in a plethora of treatment options for both patients and physicians to explore as they navigate the complexities of ITP. Dr. Waleed Ghanima will delve into the innovative strategies that incorporate combination therapies in the management of ITP, shedding light on when it may be beneficial to move beyond monotherapy. Following this, Dr. Annemarie Fogerty will provide insights into the latest developments in managing ITP during pregnancy, a unique subset of patients with implications for both maternal and fetal well-being. She will offer valuable information on treatment options and outcomes in this delicate scenario. Lastly, Dr. Michele Lambert will outline the current or recently completed clinical trials in the field of ITP, highlighting novel therapeutics in the pipeline and addressing the existing treatment gaps that warrant further investigation. This comprehensive discussion aims to equip healthcare professionals with the knowledge and tools needed to optimize patient care and outcomes in the realm of ITP.

ASH ISTH Clinical Practice Guidelines on Treatment of Venous Thromboembolism (VTE) in Pediatric Patients

  • Date/Time: Saturday, December 7, 2024, 9:30 am – 11:00 am
  • Location: San Diego Convention Center, Room 25
  • Description: This special education session will provide a preview of the revision background, including topics such as asymptomatic VTE, the duration of therapy for provoked and unprovoked VTE, and the use of anticoagulants (particularly DOACs) in pediatric patients.

Beyond TTP: “Atypical” TMAs for the Hematologist

  • Date/Time: Saturday, December 7, 2024, 2:00 pm – 3:15 pm
  • Location: San Diego Convention Center, Room 24
  • Description: The upcoming session will delve into three interconnected disease states: Transplant-Associated Thrombotic Microangiopathy (TA-TMA), Atypical Hemolytic Uremic Syndrome (aHUS), and Catastrophic Antiphospholipid Antibody Syndrome (CAPS). The discussion on TA-TMA will explore its prevalence in the post-transplant phase, the complexities of distinguishing TA-TMA from other post-transplant issues, and the latest data on innovative treatment methods. Additionally, the session will provide a thorough examination of aHUS, focusing on its genetic foundations, unusual manifestations, and advancements in targeted therapies like complement inhibitors. The conversation will delve into the intricacies of managing these atypical TMAs, showcasing case studies and clinical trials that underscore the pivotal role of personalized medicine in enhancing patient outcomes. Furthermore, the session will shed light on Catastrophic Antiphospholipid Syndrome (CAPS), a rare and severe subtype of antiphospholipid syndrome characterized by widespread microvascular thrombi that result in multiple organ failure. The presentation will offer an overview of the pathophysiology, diagnostic criteria, and emerging treatment modalities for CAPS.

Hematologic Challenges at the End-of-Life

  • Date/Time: Saturday, December 7, 2024, 2:00 pm – 3:15 pm
  • Location: San Diego Convention Center, Room 6A
  • Description: Managing hematologic conditions in patients at the end of life presents both challenges and opportunities to deliver evidence-based, compassionate care. Caring for seriously ill patients requires careful consideration of factors such as life expectancy, symptom management, and hospice care, which are relevant across various hematologic diseases. Fortunately, there is a growing body of multidisciplinary evidence to guide treatment decisions in this context. During this session, our presenters will delve into the optimization of end-of-life care for patients with transfusion-dependent hematologic malignancies. They will also explore strategies for managing anticoagulant medications in individuals with limited life expectancy. Additionally, the presenters will discuss prognostication and palliative care in sickle cell disease.

HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

  • Date/Time: Saturday, December 7, 2024, 4:00 pm – 5:15 pm
  • Location: San Diego Convention Center, Room 28 A-D
  • Description: The diagnosis and management of heparin-induced thrombocytopenia (HIT) present ongoing challenges for healthcare professionals treating hospitalized patients. This session aims to address these challenges by offering evidence-based practical guidance in the diagnosis and management of suspected and confirmed HIT. Additionally, it will classify anti-platelet factor 4 (PF4) antibody-mediated disorders, known as autoimmune HIT, and explore their relationship to heparin exposure. The session will also highlight the role of rapid PF4 and platelet activation assays in the diagnosis process. Furthermore, alternative management strategies will be reviewed for patients who do not respond to heparin cessation or non-heparin anticoagulants. This includes patients with refractory HIT, those experiencing acute bleeding, or individuals scheduled for cardiac surgery. By emphasizing evidence-based strategies, this session will provide practical approaches and system-level interventions to ensure high-quality care for patients with HIT.

Paradigm Shifts in Hemostasis: From Mechanisms to Therapies and Back

  • Date/Time: Sunday, December 8, 2024, 4:30 pm – 5:45 pm
  • Location: San Diego Convention Center, Room 28 A-D
  • Description: Coagulation is a complex and intricate process that goes beyond simply forming clots. It is a network of mechanisms and pathways that continuously evolve, with various regulations and feedback loops. The impact of coagulation extends far beyond clot formation, influencing immunity, inflammation, vascular biology, and regeneration. In this session, we will showcase three examples of how interactions between research and clinical practice have led to significant advancements in understanding the mechanisms, diagnosis, and treatment of bleeding disorders and thrombotic complications. These bi-directional exchanges have paved the way for paradigm shifts in the field, offering new insights and options for patients.

Anticoagulation SOS: Navigating Monitoring Conundrums

  • Date/Time: Monday, December 9, 2024, 10:30 am – 11:45 am
  • Location: San Diego Convention Center, Room 28 A-D
  • Description: Anticoagulation monitoring poses common challenges in clinical practice. This educational session will provide clinically oriented strategies for comprehending and addressing challenges related to monitoring anticoagulation in patients using direct oral anticoagulants (DOACs), monitoring heparin levels, and managing anticoagulation in individuals with antiphospholipid antibody syndrome.

Gene Therapy and Hemophilia A: What Is the Future of Curative Therapy in the Age of Emicizumab?

  • Date/Time: Monday, December 9, 2024, 2:45 pm – 4:00 pm
  • Location: San Diego Convention Center, Room 24
  • Description: Significant progress has been made in the treatment of hemophilia A in recent decades. The adoption of routine prophylaxis as the standard of care has resulted in many children reaching adulthood with normal joint function, and adults experiencing improved function and quality of life. Despite these advancements, there is still a treatment burden and instances of bleeding, including spontaneous hemorrhage. Newer therapeutics that have received regulatory approval or are in late-phase clinical trials show promise in reducing the treatment burden and improving efficacy. This session will provide an update on gene therapy for hemophilia and explore its potential in conjunction with other emerging therapies.

The ASH Annual Meeting promises to provide in-depth discussions on the latest advancements in hematology, providing attendees with valuable insights and knowledge to enhance their practice. We highly recommend exploring all the sessions that ASH24 has to offer by clicking here. We are eagerly anticipating an enlightening and captivating conference experience.

Sign up for alerts and stay informed on the latest published guidelines and stay tuned for our recap post the conference.

Copyright © 2024 Guideline Central, All Rights Reserved.